Transforming treatment

for chronic respiratory disease

For patients with chronic respiratory diseases, current treatments manage symptoms but can’t modify the course of disease. Clarametyx is changing that with a novel immune-enabling approach that targets the driver of many progressive lung diseases: bacterial biofilms.

Learn how it works

Meet our team: a strategically focused group of experts and advisors with deep expertise in therapeutic development and delivery.

Meet the team

In the news

April 2, 2026

Clarametyx Biosciences Strengthens Executive Leadership to Accelerate Clinical Development Efforts

Read More
January 27, 2026

Clarametyx Biosciences Strengthens Scientific Advisory Board With Expert Appointments to Advance Pipeline Programs

Read More
January 9, 2026

Clarametyx Biosciences Announces Positive Topline Data from Phase 2a Study Evaluating CMTX-101 in Cystic Fibrosis

Read More
Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.